The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (HNF4α; also known as NR2A1), a transcription factor, reverses hepatocyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival.